|
THE INITIATION AND REGULATION OF INFLAMMATION IN NEUROBLASTOMA
|
5R01CA116548-13
|
$249,638
|
$249,638
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
$1,189
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
$2,500
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S3
|
$125,004
|
$1,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-12
|
$3,203,119
|
$32,031
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Role of m6A mRNA methylation in Neuroblastoma
|
5R21CA219352-02
|
$191,227
|
$191,227
|
GREGORY, RICHARD
|
BOSTON CHILDREN'S HOSPITAL
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-05S1
|
$2,256,906
|
$180,552
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-05
|
$192,024
|
$38,405
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-05
|
$20,853,800
|
$1,668,304
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Targeting the GPC2 oncoprotein with immune-based therapies in neuroblastoma
|
1K08CA230223-01
|
$202,195
|
$202,195
|
BOSSE, KRISTOPHER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Discovering the genetic basis of neuroblastoma initiation and progression
|
1R03CA230366-01
|
$172,000
|
$172,000
|
DISKIN, SHARON
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Structural Variation in Neuroblastoma
|
5R01CA204974-03
|
$384,300
|
$384,300
|
DISKIN, SHARON
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Role of LMO1 in Neuroblastoma Initiation and Maintenance
|
5R01CA180692-04
|
$606,838
|
$606,838
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes
|
5R35CA220500-02
|
$1,032,000
|
$1,032,000
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Pediatric Preclinical Testing Consortium
|
5U01CA199287-04
|
$357,000
|
$357,000
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Targeting Oncogenic ALK Signaling in Neuroblastoma
|
5R01CA140198-10
|
$374,304
|
$374,304
|
MOSSE, YAEL
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Center for pediatric tumor cell atlas
|
1U2CCA233285-01
|
$2,560,774
|
$845,055
|
TAN, KAI
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Exosomes in tumor cell-mesenchymal stromal cell interaction
|
5R01CA207983-02
|
$449,691
|
$314,784
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Training Physician Scientists in Pediatric Oncology
|
5T32CA009659-23
|
$214,456
|
$107,228
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Clinical significance and mechanism of action of exosomal microRNAs in Neuroblastoma chemoresistance.
|
1R01CA219024-01A1
|
$123,772
|
$123,772
|
FABBRI, MULLER
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance
|
5P01CA217959-02
|
$2,171,238
|
$2,171,238
|
SEEGER, ROBERT
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
HAUSP inhibitors in p53-wild type and p53-mutant tumors
|
5R01CA193890-04
|
$366,000
|
$91,500
|
GU, WEI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma
|
1R01CA214912-01A1
|
$629,914
|
$629,914
|
DUBOIS, STEVEN
|
DANA-FARBER CANCER INST
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
5R01CA148688-07
|
$413,844
|
$413,844
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers
|
5R01CA197336-03
|
$407,748
|
$407,748
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S1
|
$445,796
|
$4,458
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S2
|
$59,495
|
$595
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S3
|
$62,500
|
$625
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S4
|
$149,528
|
$1,495
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S5
|
$60,691
|
$607
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S6
|
$228,108
|
$2,281
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S7
|
$199,806
|
$1,998
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
5P30CA006516-53
|
$11,504,298
|
$115,043
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-10S1
|
$72,918
|
$729
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-10S2
|
$200,473
|
$2,005
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-10S3
|
$234,000
|
$2,340
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
5P30CA138292-10
|
$2,574,000
|
$25,740
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Exploiting chemoimmunotherapy strategies with genetically-engineered gd T cells
|
1R21CA223300-01A1
|
$200,637
|
$200,637
|
GOLDSMITH, KELLY
|
EMORY UNIVERSITY
|
|
The Role of LIN28B Signaling in Mediating the Oncogenic Phenotype in Neuroblas
|
5K08CA194162-04
|
$168,264
|
$168,264
|
SCHNEPP, ROBERT
|
EMORY UNIVERSITY
|
|
Employing the Myc Transcriptional Network to Reveal Oncogenic Pathways
|
5R01CA057138-27
|
$635,460
|
$317,730
|
EISENMAN, ROBERT
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer Center Support Grant
|
3P30CA015704-43S1
|
$78,024
|
$2,341
|
GILLILAND, D
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer Center Support Grant
|
3P30CA015704-43S2
|
$199,999
|
$6,000
|
GILLILAND, D
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer Center Support Grant
|
3P30CA015704-43S3
|
$246,630
|
$7,399
|
GILLILAND, D
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer Center Support Grant
|
3P30CA015704-43S4
|
$225,000
|
$6,750
|
GILLILAND, D
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer Center Support Grant
|
3P30CA015704-43S5
|
$33,324
|
$1,000
|
GILLILAND, D
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer Center Support Grant
|
5P30CA015704-43
|
$9,559,285
|
$286,779
|
GILLILAND, D
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Combinations of Synergistic Bispecific Human Antibodies: A Novel Strategy for the Treatment of Neuroblastoma
|
1U01CA232490-01
|
$2,200,000
|
$2,200,000
|
OLSON, JAMES
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Neuropeptide Y (NPY) as a hypoxia-driven metastatic factor
|
5R01CA197964-04
|
$352,710
|
$176,355
|
KITLINSKA, JOANNA
|
GEORGETOWN UNIVERSITY
|
|
Georgetown University Lombardi Cancer Center Support Grant
|
3P30CA051008-25S1
|
$249,996
|
$2,500
|
WEINER, LOUIS
|
GEORGETOWN UNIVERSITY
|
|
Georgetown University Lombardi Cancer Center Support Grant
|
5P30CA051008-25
|
$2,306,055
|
$23,061
|
WEINER, LOUIS
|
GEORGETOWN UNIVERSITY
|
Total relevant funding to Neuroblastoma for this search: $30,116,194
|